NextCODE Health (Boston) has launched clinical genomic services leveraging a platform originally developed at deCODE genetics. With the advent of affordable whole-genome sequencing, NextCODE’s end-to-end solution is designed to tackle the interpretation and data management bottleneck to expedite the incorporation of sequence data into clinical care. NextCODE secured a five-year, exclusive license for the genomics platform—including the information technology (IT) infrastructure and data analysis capabilities—from Amgen, which acquired deCODE genetics in December 2012. NextCODE also secured $15 million in Series A financing in fall 2013. This is enabling NextCODE to rapidly scale the integration of its genomics services into clinical settings. NextCODE’s services include clinical- and research-grade sequencing, analysis of clients’ legacy data, genome interpretation tools, and big genomic data solutions proven scalable for the efficient management of genomic and medical data on up to hundreds of thousands of patients. Analysis and interpretation by the Clinical Sequencing Analyzer (CSA) are powered by the proprietary Genomic Ordered Relations (GOR) database. The CSA is also backed by what the company says is the world’s largest clinical genomics reference database, including more than 40 million validated variants paired with clinical data. Together the GOR and CSA enable real-time confirmation of potentially pathogenic mutations […]